FAQ / Contact

Our headquarters in Japan serves as the center of our core operations, where strategic business decisions are made by our experienced management team to guide the company's overall direction and growth. In Australia, our operations are primarily focused on preclinical testing and research, ensuring that our drug candidates meet rigorous scientific and safety standards in the early stages of development. Meanwhile, in the United States, our partner, the University of Pennsylvania, drives innovative scientific discoveries, particularly focusing on understanding the mode of action of our lead drug candidates and exploring their full therapeutic potential. This global structure allows us to leverage regional strengths, foster collaboration across borders, and accelerate our progress toward delivering impactful healthcare solutions worldwide.

Our vision is driven by a deep commitment to helping people in need by offering innovative and effective solutions to the challenges posed by current treatment options, particularly GLP-1 drugs. While recognizing the significant impact of GLP-1 therapies, we aim to address their limitations and provide complementary or alternative approaches that improve patient outcomes and quality of life. We aspire to become a global company, reaching as many individuals as possible with safe, accessible, and groundbreaking treatments. By focusing on advancing scientific discoveries and developing novel treatment methods, we seek to contribute meaningfully to the medical community and empower people worldwide to lead healthier lives. Our dedication to innovation, collaboration, and excellence ensures that we remain at the forefront of addressing unmet medical needs in obesity, skin disorders, and beyond.

We hold global exclusive patent rights issued by the University of Pennsylvania, encompassing use-claim patents for various Vitamin D analogs in the treatment of lipid and skin disorders. Additionally, we have secured a material patent on the formulation of our lead asset, H-275. These robust intellectual property protections ensure our competitive edge and provide a strong foundation for the development and commercialization of innovative therapies in the anti-obesity and related markets.

We believe our discoveries have the potential to translate into treatments for a wide range of disorders. Our primary focus is on the anti-obesity market, where early preclinical efficacy studies have demonstrated significant weight loss in small animal models. These promising results highlight the potential of our lead drug, H-275, to provide a novel and effective approach to weight management. In the medium term, we are expanding our pipeline to include treatments for skin disorders. Notably, the fat loss induced by our therapy is released through sebum secretion, which we believe could play a key role in recovering damaged skin by enhancing the skin’s natural barrier function. This mechanism offers potential therapeutic solutions for conditions such as atopic dermatitis and chronic hand eczema. Lastly, beyond therapeutic applications, we are also exploring the development of multiple assets that could be marketed as over-the-counter drugs or cosmetic products, further broadening the reach and impact of our discoveries.

The research conducted in the Kambayashi lab relates to studying the mechanisms of how the skin can control systemic processes including immune responses and metabolism.

We are proud to collaborate with esteemed research institutions in both the United States and Japan. Our partnership with the University of Pennsylvania focuses on exploring the mode of action of our drug therapy, providing critical insights into its mechanisms and potential applications. Meanwhile, our collaboration with the University of Kyushu is centered on the development of new chemical entities, enabling us to expand our pipeline and innovate further in the field of drug discovery. These partnerships exemplify our commitment to leveraging global expertise to advance impactful and scientifically rigorous solutions in the anti-obesity market.

Although GLP-1 drugs have significantly transformed the anti-obesity market, several challenges remain unresolved. Common issues include side effects, loss of muscle mass, and a high discontinuation rate among patients. When these drugs are stopped, many patients experience rapid weight rebound, highlighting the need for complementary or alternative solutions. Our drug, H-275, approaches weight management from a completely different angle. It is designed to offer minimal side effects, affordability, and ease of use, addressing the key barriers to long-term treatment adherence. Rather than competing directly with GLP-1 drugs, we envision H-275 as a complementary solution that can enhance the benefits of GLP-1 therapies. It could be used in combination with GLP-1 drugs to support a more holistic approach to weight management or as a preventive measure to sustain results after GLP-1 discontinuation. By addressing gaps in the current market, H-275 has the potential to play a pivotal role in improving patient outcomes while broadening the overall anti-obesity treatment landscape.

MC903 is the active ingredient of F-275. MC903 is an active Vitamin D3 analog that stimulates a receptor called Vitamin D3 receptor. Vitamin D3 that we consume through our diet is the inactive form of Vitamin D3. This needs to undergo further chemical modifications that are tightly regulated in the body to be activated and stimulate Vitamin D3 receptor. Thus, it is virtually impossible to deliver the amount of active Vitamin D3 that is necessary for the fat loss effect to the skin by dietary intake of Vitamin D3.

This is related to the mechanism of action of the drug. The idea of our company is to harness the potential of the skin to make our bodies healthier. In this particular example, we are using H-275 to stimulate the skin to produce substances that will increase oil secretion from the skin. This will make our skin more moisturized and have increased barrier function. The secretion of oil from the skin will also lead to reduction of body fat, which will fight against obesity-related diseases.